Newsfeeds - Spark Newswire

2 minute read

News

Halozyme Reports Tender Offer To Buy All Shares Of Antares Pharma At $5.60/Share In Cash

Today, 5:12 AM

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to

ATRS

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For April 14, 2022

By Benzinga Insights

Today, 5:12 AM

Upgrades

ADYEY

2 minute read

Looking Into Antares Pharma Inc’s Recent Short Interest

By Benzinga Insights

Today, 5:12 AM

Antares Pharma Inc's (NASDAQ:ATRS) short percent of float has risen 8.8% since its last report. The company recently reported that it has 4.49 million shares sold short, which is 2.72% of all regular shares that are available for trading.

ATRS

1 minute read

Truist Securities Downgrades Antares Pharma to Hold, Lowers Price Target to $5.6

By Benzinga Newsdesk

Today, 5:12 AM

Truist Securities analyst Gregory Fraser downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Hold and lowers the price target from $7 to $5.6.

ATRS

1 minute read

HC Wainwright & Co. Downgrades Antares Pharma to Neutral, Announces $5.6 Price Target

By Benzinga Newsdesk

Today, 5:12 AM

HC Wainwright & Co. analyst Oren Livnat downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Neutral and announces $5.6 price target.

ATRS

1 minute read

Piper Sandler Downgrades Antares Pharma to Neutral, Lowers Price Target to $5.6

By Benzinga Newsdesk

Today, 5:12 AM

Piper Sandler analyst David Amsellem downgrades Antares Pharma (NASDAQ:ATRS) from Overweight to Neutral and lowers the price target from $6 to $5.6.

ATRS

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 5:12 AM

Gainers

AGLE

1 minute read

Why Antares Pharma Stock Is Soaring Today

By Adam Eckert

Today, 5:12 AM

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing Antares at

ATRS

1 minute read

Halozyme To Acquire Antares Pharma For $5.60/Share In Cash; Transaction Values Antares At $960M

By Bill Haddad

Today, 5:12 AM

SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") today

ATRS

1 minute read

M&A
News

Wall Street Journal Reported Halozyme Therapeutics Nears Deal to Buy Antares Pharma for $5.60/Share in Cash

By Charles Gross

Today, 5:12 AM

https://www.wsj.com/articles/halozyme-therapeutics-nears-deal-to-buy-antares-pharma-11649840401#:~:text=Halozyme%20would%20pay%20%245.60%20a,value%20of%20roughly%20%24640%20million.

ATRS